Clinical Impact of Hypercalcemia in Kidney Transplant

Table 1

Prevalence of Hypercalcemia (HC) after Kidney Transplantation (KTx) in different studies.

Reference	Study; protocol	N.; of; pts	Definition of HC	Time of observation; (months from KTx)	% of HC	Vit D; suppl
David et al.; [6]	RS	64	tot-sCa >2.75 mmol/L	nd	34%	nr
Cundy et al.; [7]	POS	100	tot-sCa > 2.65 mmol/L	Multiple assessments from; the 2nd to the 24th month	12th → 20%; 24th → 12%	nr
Reinhardt et al.; [3]	POS	129	corr. tot-sCa > 2.95 mmol/L	Multiple assessments from; the 2nd to the 24th month	3rd → 52%; 12th → 23%; 24th → 10%	No
Leca et al.; [8]	nr-PIS	213	tot-sCa > 2.625 mmol/L	6th month	9.9%	No
Egbuna et al.; [9]	RS	303	corr. tot-sCa > 2.55 mmol/L	Multiple assessments from; the 2nd to the 12th month	3rd → 8%; 12th → 9%	nr
Ramezani et al.; [10]	RS	398	tot-sCa > 2.625 mmol/L	Assessment over the first12 months	4.5%	nr
Evenepoel et al.; [11]	POS	201	corr. tot-sCa or; tot-sCa; > 2.575 mmol/L	Multiple assessments over the first 3 months	corr. tot-sCa → up to 14%; tot-sCa → up to 27%	No
Evenepoel et al.; [12]	POS	268	i-sCa > 1.29 mol/L or; corr. tot-sCa; > 2.575 mmol/L	Multiple assessments over the first 12 months	i-sCa → up to 58.6%; corr. tot-sCa → up to 13.1%	nr

POR = prospective observational study, RS: retrospective study, nr-PIS: not randomized prospective intervention study, tot-sCa: total serum Calcium, corr-tot-sCa: total serum calcium corrected for albumin, i-sCa: ionized serum calcium; nd: not defined, nr: not reported.